Anaphore Will Focus On Trimeric Proteins In Auto-Immune, Oncology Settings
This article was originally published in The Pink Sheet Daily
Private biotech raises $25 million in Series A deal involving three venture capital funds.
You may also be interested in...
This past week saw two GPCR-focused deals – Shire’s optioning of a preclinical adenosine A2a antagonist and Anaphore’s acquisition of a platform company specializing in biologics targeting GPCRs.
Despite a miserable economy, new company formation continues apace. In biotech, recapitalizations and structured deals featured prominently; in diagnostics, interest remains strong even if rounds in 2008 were down from last year's highs; in devices, small and regional VCs have filled the void left by brand-name investors.
Merck BioVentures plans to launch follow-on version of Amgen’s Aranesp by 2012.